Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Carcinoma, Intraductal, Noninfiltrating

ClinicalTrials.gov lists 281 trials for Carcinoma, Intraductal, Noninfiltrating or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 13.

MeSH D002285 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 25 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 69 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 22 Phase 4 Phase 4 2 Not applicable Not applicable 94 Observational Observational 60 Phase 1 Phase 1 25 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 69 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 22 Phase 4 Phase 4 2 Not applicable Not applicable 94 Observational Observational 60

Trials per phase (log scale)

281 of the 281 trials are tagged with Carcinoma, Intraductal, Noninfiltrating itself; the rest are tagged with a narrower condition beneath it.

Get the Carcinoma, Intraductal, Noninfiltrating report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Carcinoma, Intraductal, Noninfiltrating trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 20

1991: 1 trials (Observational 1) 1995: 1 trials (Phase 2 1) 1996: 1 trials (Observational 1) 1997: 1 trials (Phase 3 1) 1999: 1 trials (Phase 3 1) 2000: 1 trials (Phase 1 1) 2001: 1 trials (Not applicable 1) 2002: 6 trials (Phase 2 5, Phase 1/2 1) 2003: 8 trials (Observational 1, Not applicable 3, Phase 3 3, Phase 2 1) 2004: 8 trials (Observational 2, Not applicable 2, Phase 2 4) 2005: 11 trials (Observational 3, Not applicable 4, Phase 3 1, Phase 1 3) 2006: 11 trials (Observational 3, Not applicable 4, Phase 2 4) 2007: 8 trials (Not applicable 6, Phase 3 1, Phase 1 1) 2008: 20 trials (Observational 6, Not applicable 6, Phase 4 1, Phase 3 3, Phase 2 2, Phase 1 2) 2009: 17 trials (Observational 6, Not applicable 4, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2010: 14 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1 3) 2011: 11 trials (Observational 2, Not applicable 4, Phase 3 2, Phase 2 2, Phase 1/2 1) 2012: 5 trials (Not applicable 3, Phase 2 2) 2013: 10 trials (Observational 2, Not applicable 4, Phase 2 3, Phase 1 1) 2014: 9 trials (Observational 2, Not applicable 5, Phase 2 1, Phase 1/2 1) 2015: 10 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2016: 12 trials (Observational 4, Not applicable 3, Phase 3 2, Phase 2 2, Phase 1 1) 2017: 13 trials (Observational 2, Not applicable 6, Phase 2/3 1, Phase 2 4) 2018: 12 trials (Observational 5, Not applicable 2, Phase 2 2, Phase 1 3) 2019: 14 trials (Observational 2, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2020: 11 trials (Observational 2, Not applicable 5, Phase 3 1, Phase 2 2, Phase 1 1) 2021: 7 trials (Observational 1, Not applicable 5, Phase 2 1) 2022: 9 trials (Observational 3, Not applicable 1, Phase 2 3, Phase 1 2) 2023: 9 trials (Observational 3, Not applicable 2, Phase 2 3, Phase 1/2 1) 2024: 12 trials (Observational 2, Not applicable 2, Phase 2 7, Phase 1 1) 2025: 14 trials (Observational 1, Not applicable 8, Phase 3 1, Phase 2 3, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 10
2025 14
2024 12
2023 9
2022 9
2021 7
2020 11
2019 14
2018 12
2017 13

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 12 trials starting in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 26 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 185 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Carcinoma, Intraductal, Noninfiltrating trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 25
Phase 1/2 8
Phase 2 69
Phase 2/3 1
Phase 3 22
Phase 4 2
Not applicable 94
Observational 60

How many Carcinoma, Intraductal, Noninfiltrating trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 9
Recruiting 40
Active, not recruiting 28
Completed 142
Suspended 5

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Carcinoma, Intraductal, Noninfiltrating trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 13

Which drugs are being tested for Carcinoma, Intraductal, Noninfiltrating? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Anastrozole 10
Exemestane 4

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tamoxifen Pill 26
Radiation Therapy 12
Adjuvant Therapy 11
Letrozol (Femara, Novartis) 8
Neoadjuvant Therapy 7

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Carcinoma, Intraductal, Noninfiltrating trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Thromboembolic event 28 4
Myocardial infarction 26 4
Osteoarthritis 26 1
Death 24 1
Ankle fracture 22 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Carcinoma, Intraductal, Noninfiltrating? (338)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial. International journal of radiation oncology, biology, physics 2026 Yes
Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis. Cancer prevention research (Philadelphia, Pa.) 2026 Yes
OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA 2025 Yes
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial. JAMA oncology 2025 Yes

Showing 5 of 338 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages